ARDX

Ardelyx Inc

Add to Watchlist

Advanced Chart

5.210

+0.07(1.362%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.2493

Open

5.190

VWAP

5.19

Vol

4.03M

Mkt Cap

1.26B

Low

5.095

Amount

20.89M

EV/EBITDA(TTM)

Total Shares

233.98M

1.20B

EV/OCF(TTM)

P/S(TTM)

3.17

Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing first-in-class medicines. The Company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q2

102.04M

+37.67%

-0.033

-266.3%

112.75M

-2.91%

-0.137

+95.54%

Estimates Revision

The market is revising Downward the revenue expectations for Ardelyx, Inc. (ARDX) for FY2025, with the revenue forecasts being adjusted by -2.39% over the past three months. During the same period, the stock price has changed by 43.13%.

Revenue Estimates for FY2025

Revise Downward

-2.39%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.37%

In Past 3 Month

Stock Price

Go Up

+43.13%

In Past 3 Month

10 Analyst Rating

115.36% Upside

Wall Street analysts forecast ARDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDX is 11.22 USD with a low forecast of 8.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

0 Hold

0 Sell

Strong Buy

115.36% Upside

Current: 5.210

Low

8.00

Averages

11.22

High

15.00

115.36% Upside

Current: 5.210

Low

8.00

Averages

11.22

High

15.00

Piper Sandler

Neutral

maintain

$8 -> $9

2025-08-06

New

Reason

Piper Sandler

Price Target

$8 -> $9

2025-08-06

New

maintain

Neutral

Reason

Piper Sandler raised the firm's price target on Ardelyx to $9 from $8 and keeps a Neutral rating on the shares. The firm is incrementally positive on the name following Q2 2025 reporting. That said, with management still not committing to Xphozah guidance this year but continuing to guide to $750M in peak U.S. sales before patent expiry, the firm continues to look for a better sense of uptake and the near- and immediate-term outlook for this drug before getting more constructive on the name.

Raymond James

Outperform

maintain

$11 -> $12

2025-08-05

New

Reason

Raymond James

Price Target

$11 -> $12

2025-08-05

New

maintain

Outperform

Reason

Raymond James raised the firm's price target on Ardelyx to $12 from $11 and keeps an Outperform rating on the shares. The substantial consensus beat and return to quarter over quarter growth suggests unfavorable Q1 seasonality is likely to remain prominent in out years, but also de-risks Ibserla guidance as well as the peak sales target for Xphozah, the analyst tells investors in a research note.

Wedbush

Outperform

maintain

$13 -> $14

2025-08-05

New

Reason

Wedbush

Price Target

$13 -> $14

2025-08-05

New

maintain

Outperform

Reason

Wedbush raised the firm's price target on Ardelyx to $14 from $13 and keeps an Outperform rating on the shares. The firm notes Ardelyx posted a solid performance in Q2 with total revenue beating by $16M, driven by Ibsrela strength. Management increased the FY25 Ibsrela guidance range to $250M-$260M and Wedbush thinks this is an achievable bar. Finally, Ardelyx announced multiple leadership changes and CFO Justin Renz will exit the company in the coming months.

Jefferies

Buy

maintain

2025-07-02

Reason

Jefferies

Price Target

2025-07-02

maintain

Buy

Reason

Jefferies reiterated a Buy rating and $8 price target on Ardelyx. The firm noted that the stock is trading 5%-10% higher Wednesday morning on a sizable volume, and that it's unclear why. A potential reason could be from an update on the Xphozah CMS appeal, which Jefferies has been flagging as a significant call option not in buyside expectations, the analyst tells investors in a research note. The firm added that a new docket update this week set a date for oral arguments in September 25, and that a positive appeals decision by the end of the year could restore Part D for Xphozah and add a large growth driver for the stock.

H.C. Wainwright

initiated

$10

2025-06-19

Reason

H.C. Wainwright

Price Target

$10

2025-06-19

initiated

Reason

H.C. Wainwright assumed coverage of Ardelyx with a Buy rating and $10 price target. The company has demonstrated approval and commercial execution with Ibsrela for the treatment of irritable bowel syndrome with constipation in adults and Xphozah for treating hyperphosphatemia, the analyst tells investors in a research note. The firm sees near-term commercial progress for Ardelyx.

Scotiabank

Louise Chen

Buy

Initiates

$15

2025-03-07

Reason

Scotiabank

Louise Chen

Price Target

$15

2025-03-07

Initiates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Ardelyx Inc (ARDX.O) is -27.31, compared to its 5-year average forward P/E of -11.44. For a more detailed relative valuation and DCF analysis to assess Ardelyx Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.44

Current PE

-27.31

Overvalued PE

-1.76

Undervalued PE

-21.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-14.89

Current EV/EBITDA

25.58

Overvalued EV/EBITDA

26.12

Undervalued EV/EBITDA

-55.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

29.70

Current PS

2.91

Overvalued PS

84.71

Undervalued PS

-25.31